Alfentanil
Subcutaneous | |
| ATC code | |
|---|---|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ~50% |
| Protein binding | 92% |
| Metabolism | Hepatic |
| Elimination half-life | 90–111 minutes |
| Duration of action | 15 min[2] |
| Identifiers | |
| |
JSmol) | |
| Melting point | 140.8 °C (285.4 °F) |
| |
| |
| (verify) | |
Alfentanil (R-39209, trade name Alfenta, Rapifen in Australia) is a potent but short-acting synthetic
mu opioid receptors
.
While alfentanil tends to cause fewer
respiratory depression and so requires careful monitoring of breathing and vital signs. Almost exclusively used by anesthesia providers during portions of a case where quick, fast-acting (though not long-lasting) pain control is needed (as, for example, during nerve blocks), alfentanil is administered by the parenteral
(injected) route for fast onset and precise control of dosage.
Discovered at
Janssen Pharmaceutica in 1976, alfentanil is classified as a Schedule II drug in the United States.[4]
Side effects of
respiratory depression. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.[5]
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ISBN 9781890883539.
- ^ Jacob Mathew, J. Kendall Killgore. Methods for the synthesis of alfentanil, sufentanil, and remifentanil. US Patent 7,208,604
- ^ "From DEA website, accessed 23 Jan 2007". Archived from the original on 2007-02-02. Retrieved 2007-01-23.
- PMID 25976511.
External links
- Medline Plus Patient Information - 09/01/2010
- https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm February 2017
- Genf interaction table- https://www.hug.ch/sites/interhug/files/structures/pharmacologie_et_toxicologie_cliniques/carte_cytochromes_2016_final.pdf February 2017